SCHEMBL10163556

SCHEMBL10163556

Cc1ccc(CNC(=O)c2cc(C(=O)NCc3ccc4oc(=O)n(C)c4c3)nc3ccnn23)c(C(N)=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
MMP13 P45452 2/20 0.38
ADAMTS4 O75173 1/20 0.38
MMP3 P08254 1/20 0.38
MMP8 P22894 1/20 0.38
MMP12 P39900 1/20 0.38
TP53 P04637 5/20 0.38
LMNA P02545 4/20 0.38
RXFP1 Q9HBX9 2/20 0.38
POLB P06746 4/20 0.36
KMT2A Q03164 5/20 0.36
MEN1 O00255 3/20 0.36
THRB P10828 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228905 0.92 ADAMTS4 (0.36) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10208198 0.92 ALDH1A1 (0.38) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL10162840 0.90 L3MBTL1 (0.48) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL8229036 0.89 KMT2A (0.40) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL8228662 0.88 MMP13 (0.39) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL10208196 0.88 MMP13 (0.38) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL10163516 0.88 MMP13 (0.41) L3MBTL1MMP13ADAMTS4MMP3TP53
SCHEMBL10162848 0.87 POLB (0.48) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL10208197 0.87 TP53 (0.39) L3MBTL1MMP13ADAMTS4MMP3MMP8
SCHEMBL10162863 0.86 ALDH1A1 (0.38) L3MBTL1MMP13ADAMTS4MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885MMP13 1/4885ADAMTS4 38/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 L3MBTL1 4566/4885MMP13 1/4885ADAMTS4 38/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885MMP13 1/4885ADAMTS4 38/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885MMP13 1/4885ADAMTS4 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.